Free Trial

HC Wainwright's Rating of Zenas BioPharma on 10/13/2026

On October 13, 2026, HC Wainwright updated its outlook on Zenas BioPharma (NASDAQ:ZBIO) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from HC Wainwright

DateCompanyAction
10/13/2026
GRI Bio, Inc. stock logo
GRI
GRI Bio
Reiterated Rating
10/13/2026
Envoy Medical, Inc. stock logo
COCH
Envoy Medical
Reiterated Rating
10/13/2026
AngioDynamics, Inc. stock logo
ANGO
AngioDynamics
Lower Price Target
10/13/2026
Incyte Corporation stock logo
INCY
Incyte
Reiterated Rating
10/13/2026
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Reiterated Rating
10/13/2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
Reiterated Rating
More Ratings From HC Wainwright